GRI Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Keller initiated coverage of GRI Bio (GRI) with a Buy rating and $10 price target GRI is a clinical stage company developing therapies that modulate natural killer T cell behavior and activity in inflammatory diseases, the analyst tells investors in a research note. The firm believes the combination of two immunomodulatory assets and a library of potentially applicable compounds positions GRI Bio to progress its pipeline in-house, while taking advantage of potential strategic partnerships.